TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo.

@article{Zhang2013TLR9mediatedSD,
  title={TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo.},
  author={Qifang Zhang and Dewan Md Sakib Hossain and Sergey Nechaev and Anna Kozlowska and Wang Zhang and Yong Liu and Claudia M. Kowolik and Piotr Swiderski and John J. Rossi and Stephen J. Forman and Sumanta Pal and Ravi Bhatia and Andrew A. Raubitschek and Hua Yu and Marcin Kortylewski},
  journal={Blood},
  year={2013},
  volume={121 8},
  pages={1304-15}
}
STAT3 operates in both cancer cells and tumor-associated immune cells to promote cancer progression. As a transcription factor, it is a highly desirable but difficult target for pharmacologic inhibition. We have recently shown that the TLR9 agonists CpG oligonucleotides can be used for targeted siRNA delivery to mouse immune cells. In the present study, we demonstrate that a similar strategy allows for targeted gene silencing in both normal and malignant human TLR9(+) hematopoietic cells in… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS